Peter Attia Longevity Framework: Medicine 3.0

Marcus had a collection of fitness trackers that would make a tech journalist weep. Whoop on his wrist. Oura ring on his finger. CGM sensor on his arm. He tracked his HRV, his sleep stages, his blood glucose curves, his VO2 max trends. He had more data on his body than most cardiologists have on their patients.

He was also on track to die from the same four things that kill most people: cardiovascular disease, cancer, neurodegenerative disease, or metabolic dysfunction.

Not because he was unhealthy — he was reasonably fit. But because he was doing what most health-conscious people do: optimizing for symptoms rather than causes, reacting to today’s metrics rather than building against tomorrow’s death.

Marcus discovered Peter Attia’s work through a podcast and spent the next month reading everything the physician had written. What he found wasn’t a new supplement stack. It was a reframing so fundamental it made most of his previous health efforts look like decorating the outside of a house with a structural problem in the foundation.

That reframing is what this article is about.

Medicine 2.0 vs. Medicine 3.0: The Framework That Changes Everything

Peter Attia, a physician and researcher who has spent the better part of a decade becoming one of the most rigorous thinkers in the longevity medicine space, draws a sharp distinction between two medical paradigms.

Medicine 2.0 — the current standard of care — is reactive, disease-focused, and structured around treating established illness. You develop type 2 diabetes, and Medicine 2.0 treats your diabetes. You have a heart attack, and Medicine 2.0 stabilizes you. You show signs of cognitive decline, and Medicine 2.0 manages your symptoms.

Medicine 2.0 is genuinely good at acute illness. It fails catastrophically at the slow, chronic killers — the diseases of aging that develop over decades and are largely determined by decisions made long before the first symptom appears.

The problem isn’t negligence. It’s architecture. Medicine 2.0 was built to treat disease once it exists. It was not built to prevent the conditions that, in the developed world, kill most people.

Medicine 3.0, as Attia describes it, is fundamentally different in its orientation. Rather than waiting for disease, it asks: what are the probabilities that this specific individual will develop the four major disease categories, and what interventions today change those probabilities? Rather than treating established dysfunction, it works backward from the destination — a long, functional, cognitively intact life — and builds the plan from there.

Medicine 3.0 treats the individual rather than the population. It uses biomarker data proactively rather than reactively. It acknowledges that the interventions required to prevent cardiovascular disease at 75 begin in earnest at 35 or 45 — not when symptoms appear.

The distinction matters because it completely reorients which actions are worth taking. Many things that seem important from a Medicine 2.0 perspective — managing symptoms, staying within “normal” reference ranges — look insufficient or even misdirected from a Medicine 3.0 perspective.

“Normal is not the same as optimal. Reference ranges on lab tests represent the average of a moderately unhealthy population. Being in the bottom third of ‘normal’ for VO2 max means you’re at substantially elevated all-cause mortality risk. Medicine 3.0 doesn’t aim for normal. It aims for the range associated with the best outcomes in the research literature.”

The Four Horsemen: What Actually Kills You

• Cardiovascular disease: The leading cause of death globally. Atherosclerosis — the progressive narrowing and hardening of arteries due to plaque accumulation — is the underlying process. It begins in the second and third decades of life and progresses silently for decades before manifesting as heart attacks, strokes, or sudden cardiac death. The key insight Attia emphasizes: by the time symptoms appear, atherosclerosis is already advanced. Prevention must begin decades earlier.
• Cancer: The second horseman. Actually a family of diseases united by the common mechanism of uncontrolled cell growth. While much of cancer risk is genetic, lifestyle factors — obesity, chronic inflammation, carcinogens, metabolic dysfunction — profoundly influence cancer risk and progression. The metabolic connection to cancer is increasingly well-established: cancer cells are preferential users of glucose (the Warburg effect), and metabolic health interventions appear to meaningfully reduce risk.
• Neurodegenerative disease: Alzheimer’s disease, Parkinson’s, and other neurodegenerative conditions are the horseman that terrifies most people. The connection to metabolic health is now clearer than ever — Alzheimer’s is increasingly understood as having significant metabolic components, with insulin resistance in the brain playing a central role. APOE4 genotype is the strongest genetic risk factor; exercise is the strongest modifiable protective factor.
• Metabolic disease: Type 2 diabetes and its relatives — insulin resistance, non-alcoholic fatty liver disease, metabolic syndrome — are not just diseases in themselves but accelerants of all three other horsemen. Metabolic dysfunction raises cardiovascular risk, inflammation (which promotes cancer), and Alzheimer’s risk simultaneously. Attia treats metabolic health as the foundational domain — fix the metabolic foundation and you reduce risk across all four categories.

Attia’s framework begins with a brutally honest accounting of cause of death. Not what people fear (plane crashes, violence, rare diseases) — what actually kills people in wealthy, modern societies.

The four horsemen, as Attia calls them, account for the overwhelming majority of non-accidental deaths in developed countries:

The critical insight is that these four aren’t separate problems requiring separate solutions. They share deep mechanistic roots: chronic inflammation, insulin resistance, oxidative stress, poor metabolic health, and insufficient physical activity. Intervening on these root causes reduces risk across all four categories simultaneously.

The Centenarian Decathlon: Reverse-Engineering Your Future Self

One of Attia’s most useful conceptual tools is what he calls the “Centenarian Decathlon” — a thought experiment that reframes how you should think about fitness goals.

The premise: imagine yourself at age 90 or 100. What physical capabilities do you want to have at that age? Perhaps you want to be able to pick up a grandchild. To climb stairs without assistance. To carry your own groceries. To hike a moderate trail. To maintain your balance on an uneven surface. To get up off the floor unassisted if you fall.

These seem like modest goals. They’re not — not if you think clearly about the trajectory required to achieve them.

Physical capacity declines predictably with age. After about age 30, muscle mass decreases roughly 3-8% per decade under sedentary conditions. VO2 max declines approximately 10% per decade after the peak years. Bone density decreases, balance degrades, grip strength falls.

If you want to be able to carry 30 pounds at age 85, and you know that strength will decline roughly 30-50% from its peak in the intervening years, you need to be substantially stronger today than the load you’ll need to carry then. If you want to maintain the aerobic capacity to climb three flights of stairs at 85 without distress, you need a VO2 max now that’s high enough that even after decades of normal decline, you’ll remain above the threshold.

The Centenarian Decathlon forces backward calculation from the destination. It’s not “how do I get six-pack abs for summer” — it’s “what level of functional capacity must I build and maintain now so that I retain the abilities I value in the final decade of my life?”

This reframing has practical implications. It means prioritizing the physical domains — cardiovascular fitness, muscular strength, mobility, and balance — that actually determine whether you spend your last decade active or dependent. It means starting earlier than feels necessary, because the maintenance of high physical capacity requires a high starting point. And it means treating physical deterioration not as inevitable but as a planning problem.

Exercise as the Most Potent Longevity Drug

If a pharmaceutical company produced a drug that reduced all-cause mortality by 30-40%, improved cardiovascular health, enhanced insulin sensitivity, boosted cognitive function, reduced cancer risk, improved mood, enhanced immune function, preserved muscle mass, and strengthened bones — with side effects limited to temporary soreness — it would be the most important medical discovery in history.

That drug exists. It’s called exercise. And no pharmaceutical compound in the longevity pipeline comes close to matching its effect size on total human health outcomes.

Attia is emphatic about this in his writing and lectures: exercise is not one component among many. It is, by a significant margin, the most powerful longevity intervention available to most people. Everything else — nutrition, sleep, supplements, pharmacology — matters, but exercise matters more.

The cardiovascular benefit is enormous. Low cardiorespiratory fitness (VO2 max in the bottom 25%) is associated with 2-3x higher all-cause mortality compared to even modest fitness levels. Moving from “low” to “moderate” fitness reduces all-cause mortality risk more than any single medication or supplement studied. Moving from “moderate” to “high” fitness provides additional substantial benefit.

The muscular strength component is equally critical and often underemphasized in longevity discussions dominated by cardiovascular fitness. Grip strength, leg press performance, and general muscular strength are among the strongest predictors of longevity in mid-life and beyond. Sarcopenia — age-related muscle loss — is not just a quality-of-life issue. It’s a mortality issue. Muscle tissue is metabolically active, insulin-sensitive, and mechanically protective. Preserving and building it throughout life is not optional for the person who wants to age well.

Attia’s prescription, synthesizing the research: train all three energy systems. Zone 2 cardio (conversational-pace steady state) for metabolic health and mitochondrial density — 3-4 hours per week. High-intensity interval training or zone 5 efforts for VO2 max — once or twice weekly. Strength training 3+ days per week with sufficient intensity to progressively overload the musculoskeletal system. Add stability and mobility work to maintain the physical infrastructure that allows the other training to continue safely.

Zone 2 Training: The Underappreciated Foundation

If you’ve heard of Attia’s work, you’ve likely heard about Zone 2. It’s become the vocabulary of longevity fitness discussions, and for good reason — the physiology behind it is robust and the evidence for its metabolic benefits is compelling.

Zone 2 is a training intensity defined by lactate production and clearance. Technically, it’s the highest intensity at which lactate production equals lactate clearance — sometimes called the “first lactate threshold.” Practically, it’s the pace at which you can hold a conversation but would find it somewhat labored — roughly 60-75% of maximum heart rate for most people.

At Zone 2 intensity, you’re primarily using fat as fuel. This matters because it trains the metabolic machinery that underlies metabolic health. Specifically, Zone 2 training improves mitochondrial density (more mitochondria per cell), mitochondrial efficiency (each mitochondrion works better), and fat oxidation capacity (you burn fat more readily at all intensities).

The metabolic health implications are profound. Poor fat oxidation capacity is a central feature of insulin resistance and metabolic syndrome. When cells can’t efficiently burn fat, they default to glucose burning, which is less efficient, generates more oxidative stress, and contributes to the metabolic dysfunction that underlies all four horsemen.

Attia recommends roughly 3-4 hours of Zone 2 per week as a baseline. This is substantially more than most fitness-minded people actually do — most cardio training happens either too easy (which doesn’t provide adequate metabolic stimulus) or too hard (Zone 4-5, which provides VO2 max benefit but not the same metabolic adaptation).

The practical challenge: Zone 2 is boring by most standards. It’s slow enough that your ego protests. Many high-achieving people find themselves unable to resist pushing harder. A lactate meter — measuring fingertip blood lactate during workouts — is the most reliable way to verify you’re in Zone 2, though heart rate is a reasonable proxy once you’ve calibrated it.

Nutrition in Medicine 3.0: The Principled Pragmatist Approach

1. Metabolic flexibility: The ability to switch efficiently between burning fat and burning glucose. Chronic high-carbohydrate, high-insulin diets impair fat oxidation capacity. Periodic reduction in carbohydrate intake, time-restricted eating, or other strategies that restore metabolic flexibility are valuable for anyone showing signs of insulin resistance.
2. Avoiding hyperpalatable junk: Ultra-processed foods drive passive overconsumption, undermine satiety signaling, and are strongly associated with worse health outcomes across virtually every relevant endpoint. This isn’t a controversial position — it’s where the epidemiology and mechanistic evidence converge.
3. Consistent, sustainable patterns over dietary purity: The best diet is the one that maintains adequate protein, avoids excessive hyperpalatable ultra-processed food, and that you can actually sustain over years and decades. Perfection followed by abandonment beats imperfection less than imperfection sustained indefinitely.

Attia is notably pragmatic — and importantly, humble — about nutrition compared to many voices in the longevity space. He doesn’t align rigidly with any particular dietary philosophy (ketogenic, carnivore, plant-based) because he believes the evidence doesn’t justify such rigidity and that individual variation in response to dietary approaches is substantial.

What he is emphatic about is protein. The research on protein intake for muscle preservation and longevity is among the most consistent findings in the nutrition literature. His recommendation — 1.6 to 2.2 grams of protein per kilogram of body weight per day — is substantially higher than traditional dietary guidelines (0.8g/kg) and requires active effort to achieve.

This matters because muscle is the organ of longevity — the metabolically active tissue that determines insulin sensitivity, physical function, and structural protection against the injuries of aging. Sarcopenia is, at its root, a protein utilization problem compounded by insufficient protein intake and inadequate resistance training stimulus. Both halves of that equation need addressing.

Beyond protein, Attia’s nutritional framework focuses on:

Sleep: The Non-Negotiable Pillar

Attia places sleep alongside exercise as a non-negotiable foundation of longevity — and the research supports this emphasis. Chronic sleep deprivation (below 7 hours per night) is associated with dramatically elevated risk across all four horsemen:

Cardiovascular risk increases substantially with habitual short sleep. A meta-analysis by Cappuccio et al. found that sleeping 5 or fewer hours per night was associated with roughly 50% higher risk of cardiovascular events compared to 7-8 hours. Even 6 hours — what many busy people consider “enough” — carries measurable cardiovascular risk compared to optimal sleep duration.

Cancer risk is elevated with sleep disruption, particularly through disruption of circadian biology and melatonin production. Night-shift workers, who chronically disrupt circadian rhythms, show elevated rates of several cancers.

Alzheimer’s risk is acutely sensitive to sleep quality. Amyloid-beta — the protein that accumulates in Alzheimer’s disease — is cleared during sleep via the glymphatic system. A single night of sleep deprivation measurably increases amyloid-beta in cerebrospinal fluid. Chronic sleep insufficiency appears to drive the amyloid accumulation that precedes clinical Alzheimer’s by years to decades.

Metabolic health deteriorates rapidly with sleep insufficiency. Insulin sensitivity decreases measurably after even two or three nights of inadequate sleep. Hunger hormones (ghrelin up, leptin down) shift toward overconsumption. The metabolic consequences of chronic mild sleep deprivation compound over years in ways that conventional medicine has been slow to recognize.

The Medicine 3.0 approach to sleep is architectural: design your schedule and environment to prioritize 7-9 hours of quality sleep, not as a luxury but as a non-negotiable health intervention. This often requires harder lifestyle choices than taking a supplement — protecting sleep means saying no to late evenings, managing alcohol (which fragments sleep architecture even if it aids sleep onset), and creating the light and temperature conditions that support circadian biology.

Emotional Health: The Overlooked Horseman

Attia has been refreshingly candid about his own struggles with emotional health — what he describes as his most difficult and most important work. In his framework, emotional health is a fifth domain alongside exercise, nutrition, sleep, and pharmacology — and it’s the one that receives the least attention in most longevity discussions.

This isn’t therapy-speak. It’s biology. Chronic psychological stress drives cortisol elevation, which drives insulin resistance, systemic inflammation, and accelerated cardiovascular risk. Chronic loneliness — increasingly documented as a physical health crisis rather than merely an emotional one — is associated with mortality risk comparable to smoking 15 cigarettes per day. Anxiety disorders and depression are associated with accelerated biological aging at the cellular level, measurable through telomere length and epigenetic clock assessments.

The mechanism is direct: the psyche is not separate from the body. Unresolved psychological dysfunction activates the same physiological stress pathways that accelerate all four horsemen. You cannot outrun the biology of a chronically dysregulated nervous system with supplements and exercise protocols.

Attia’s personal work has included intensive psychotherapy to address patterns that were undermining his relationships and his health despite his extraordinary medical knowledge. He is explicit that this was the hardest and most important health intervention he undertook — and that no amount of biological optimization was a substitute for it.

For the purposes of this framework, the point isn’t a prescription for any particular psychological intervention. It’s the recognition that emotional health belongs in the longevity framework — not as a soft adjunct, but as a biological necessity with hard causal connections to the diseases we’re trying to prevent.

The Medicine 3.0 Personal Protocol Framework

The Medicine 3.0 Personal Protocol is not a single regimen. It’s a decision-making framework — a way of approaching your health that begins with honest assessment and builds interventions around your specific risk profile and goals.

• Step 1 — Define your Centenarian Decathlon: Write down the specific physical and cognitive capabilities you want at age 85-95. Be concrete. These become your destination and determine the slope of the trajectory you need to build.
• Step 2 — Assess your horseman risk profile: Family history, genetics (APOE4 status for Alzheimer’s, lipid genetics, cancer family history), and current biomarkers define your starting risk. This isn’t about fear — it’s about prioritization. If you have strong family history of cardiovascular disease, that horseman deserves the most aggressive intervention. If metabolic dysfunction is your primary risk, that’s where leverage is highest.
• Step 3 — Establish baseline biomarkers: Fasting glucose and insulin, HbA1c, lipid particle counts (LDL-P and ApoB, not just standard LDL cholesterol), hsCRP, DEXA body composition, VO2 max testing, and grip strength or other functional strength measures. These give you the starting point against which interventions are measured.
• Step 4 — Build the exercise architecture: Zone 2 cardio foundation (3-4 hours/week), VO2 max work (1-2 sessions/week), strength training (3+ days/week), and stability/mobility work. This is the highest-leverage intervention available to most people and should be the largest time investment in the protocol.
• Step 5 — Optimize nutrition around protein and metabolic health: Attia’s protein figure, 1.6-2.2g/kg daily, anchors this step. Eliminate or minimize ultra-processed hyperpalatable food. Design eating patterns that support metabolic flexibility. Adjust carbohydrate intake based on metabolic markers.
• Step 6 — Protect sleep architecture: 7-9 hours. Consistent sleep and wake times. Dark, cool environment. Minimize alcohol. Manage evening light exposure. This is frequently the intervention with the most immediate measurable impact on how you feel and function.
• Step 7 — Address psychological foundations: Honest self-assessment of stress patterns, relationship quality, purpose and meaning, and emotional regulation. This is not optional decoration — it’s structural biology.
• Step 8 — Consider targeted pharmacology: For appropriate individuals with specific risk profiles: statins or PCSK9 inhibitors for elevated ApoB/LDL-P, metformin for metabolic risk, rapamycin for overall longevity enhancement (see the companion article on rapamycin and mTOR for the evidence base). Pharmacology in Medicine 3.0 is used precisely and proactively, not as rescue after disease has developed.

The Numbers That Actually Matter: ApoB and Metabolic Markers

One of Attia’s most important practical contributions is clarity about which biomarkers actually predict cardiovascular and metabolic outcomes, versus the ones that get measured routinely but provide less actionable information.

The standard lipid panel — total cholesterol, LDL, HDL, triglycerides — is a blunt instrument. The LDL number on a standard panel measures LDL cholesterol concentration, not the number of LDL particles. Two people can have the same LDL cholesterol but dramatically different cardiovascular risk if one has many small, dense LDL particles and the other has fewer, larger particles.

ApoB (apolipoprotein B) provides a direct count of atherogenic lipoprotein particles — each LDL, VLDL, and IDL particle carries one ApoB molecule. ApoB is arguably the single best blood biomarker of cardiovascular risk and the one Attia prioritizes. He recommends an ApoB target well below 70 mg/dL for most people, and even lower for those with elevated risk.

On the metabolic side, fasting insulin is more sensitive than fasting glucose for detecting early insulin resistance. Many people have “normal” fasting glucose (below 100 mg/dL) while already showing significant insulin resistance — the pancreas is working overtime to maintain that normal glucose number. Fasting insulin above 7-10 µIU/mL, in the context of other metabolic signals, suggests insulin resistance even with normal glucose. HOMA-IR combines both numbers into a single insulin resistance estimate.

The DEXA scan, though primarily associated with bone density, provides precise body composition data — lean mass versus fat mass, regional fat distribution. Visceral fat (fat stored around organs in the abdominal cavity) is metabolically distinct from subcutaneous fat and disproportionately drives insulin resistance, inflammation, and cardiovascular risk. Knowing your visceral fat level provides information that BMI completely misses.

VO2 max is the single most powerful longevity biomarker. Studies consistently show that low VO2 max is among the strongest predictors of all-cause mortality — more predictive than smoking status, hypertension, or diabetes in many analyses. Attia uses a graded exercise test to measure VO2 max directly rather than relying on estimates.

Moving from the bottom quartile to even the middle quartile of VO2 max for your age is associated with a dramatic reduction in mortality risk.

FAQ

1. What is Peter Attia’s main longevity recommendation? Exercise — specifically the combination of Zone 2 cardio, VO2 max training, and strength training — is Attia’s highest-priority longevity recommendation. No supplement or drug matches its effect size on total health outcomes. The pharmacological interventions he discusses are additions to, not substitutes for, an intensive exercise foundation.
2. What is the Centenarian Decathlon? A conceptual framework where you define the specific physical capabilities you want at age 90-100, then reverse-engineer the fitness level you need to build now to arrive at that destination after decades of expected physiological decline. It reorients fitness goals from appearance or current performance to long-term functional capacity.
3. What does Peter Attia say about diet? Attia avoids rigid dietary prescriptions because he believes individual variation is too large for universal rules. His consistent emphases are: adequate protein (1.6-2.2g/kg body weight daily), minimizing ultra-processed hyperpalatable food, and maintaining metabolic flexibility. He uses ketogenic or low-carbohydrate approaches selectively, particularly for people with significant insulin resistance.
4. What is ApoB and why does Attia emphasize it? ApoB (apolipoprotein B) is a protein that coats all atherogenic lipoprotein particles. Measuring ApoB provides a direct count of these particles — a more accurate indicator of cardiovascular risk than standard LDL cholesterol. Attia prioritizes ApoB as the primary lipid marker to track and target.
5. How much Zone 2 cardio does Peter Attia recommend? Approximately 3-4 hours per week. This should be at the first lactate threshold — the pace at which you can hold a conversation but feel somewhat challenged. Most people’s “easy” cardio is below Zone 2; most people’s “moderate” cardio is above Zone 2. A lactate meter is the most accurate way to find and maintain the target zone.
6. Does Peter Attia take rapamycin? Attia has publicly discussed taking rapamycin as part of his longevity protocol. He’s been transparent that this is off-label use based on animal data and mechanistic reasoning rather than completed human longevity trials. He advocates for physician supervision and monitoring for anyone considering it.
7. What does “Medicine 3.0” mean? Medicine 3.0 is Attia’s framework for a proactive, individual-specific approach to health that aims to delay or prevent the four major disease categories (cardiovascular disease, cancer, neurodegeneration, metabolic disease) through early intervention, rather than treating disease after it has developed. It’s defined by individualized biomarker assessment, prevention-focused interventions, and longer time horizons than standard medical practice.
8. What is the single most important longevity biomarker? VO2 max, by most analyses. Cardiorespiratory fitness as measured by VO2 max is one of the strongest predictors of all-cause mortality across multiple large studies. Low fitness is associated with 2-5x higher mortality compared to high fitness, making it more predictive than many traditional risk factors. Improving VO2 max — through Zone 2 and higher-intensity training — is among the highest-leverage biological interventions available.

Cancer Prevention Through a Metabolic Lens

Cancer in the Medicine 3.0 framework is not primarily a genetic fatality — it’s a disease with significant metabolic modifiability. This framing is not dismissive of genuine genetic risk factors (BRCA mutations, Lynch syndrome, etc.) — it’s a correction to the common assumption that cancer is fundamentally beyond lifestyle influence.

The data tells a different story. Obesity is now recognized as the second-leading modifiable risk factor for cancer after smoking, associated with elevated risk for at least 13 different cancer types. The mechanisms are multiple: elevated circulating insulin and IGF-1 (both powerful growth signals for cells, including malignant ones), chronic inflammation, sex hormone dysregulation, and impaired immune surveillance.

Physical activity, independent of weight, is associated with reduced risk for multiple cancers — colon, breast, endometrial, and others. The mechanisms include improved immune surveillance, reduced inflammatory markers, lower circulating insulin, and possibly direct effects on tumor microenvironments through exercise-induced circulating factors.

Early detection — the aspect of cancer prevention most amenable to Medicine 3.0’s proactive orientation — is dramatically more effective than treatment of advanced disease. Whole-body MRI scanning, liquid biopsy (cancer DNA in blood), and lung CT scans for smokers are among the tools that Medicine 3.0 practitioners use for cancer surveillance in higher-risk individuals. The costs and benefits of these approaches are still being worked out in the research literature, but the principle — detect early, when treatment options are most effective — is unambiguous.

The takeaway for practical cancer prevention: maintain metabolic health (reduces insulin, IGF-1, and inflammation), exercise regularly (improves immune surveillance and reduces inflammatory burden), avoid tobacco (the most important single carcinogen exposure for most people), minimize alcohol (dose-dependent carcinogen), and consider appropriate screening based on your family history and risk profile.

Neurodegeneration Prevention: What Actually Works

Alzheimer’s disease is the horseman that generates the most fear and the most misinformation. The supplement industry has built a billion-dollar market on fear of cognitive decline, largely selling products with weak or nonexistent evidence. The Medicine 3.0 approach starts with what the evidence actually supports.

The APOE4 allele is the most important genetic risk factor for late-onset Alzheimer’s. One copy of APOE4 increases lifetime risk 2-3x; two copies increases it 8-12x. Genetic testing (23andMe or direct APOE testing) can identify this risk — though what you do with that information requires careful thought and ideally counseling.

Exercise is the most evidence-supported modifiable protective factor for Alzheimer’s. The mechanisms are multiple: exercise promotes BDNF (brain-derived neurotrophic factor) production, improves cerebral blood flow, reduces insulin resistance in the brain, improves sleep quality (and therefore amyloid clearance), and reduces systemic inflammation.

Insulin resistance in the brain — sometimes called “type 3 diabetes” — appears to be a central feature of Alzheimer’s pathology in many patients. Metabolic interventions that improve insulin sensitivity throughout the body (exercise, dietary changes, time-restricted eating) may have direct neuroprotective effects through this mechanism.

Sleep, as discussed earlier, is essential for amyloid clearance. The glymphatic system — the brain’s waste-clearance network that operates primarily during sleep — clears amyloid-beta and other metabolic waste products. Chronic sleep insufficiency impairs this clearance and may contribute to pathological amyloid accumulation over decades.

Social connection and intellectual engagement — learning new skills, maintaining complex social relationships, pursuing cognitively demanding activities — are consistently associated with reduced dementia risk in epidemiological studies. The mechanisms likely involve cognitive reserve: a richer neural network with more redundant connections that can sustain damage before clinical symptoms emerge.

Longevity Pharmacology: The Emerging Toolkit

Beyond rapamycin, which warrants its own dedicated article, the Medicine 3.0 pharmacological toolkit includes several compounds with meaningful evidence bases for specific risk profiles.

Statins and PCSK9 inhibitors for ApoB lowering: Attia is notably more aggressive than most conventional physicians about lipid-lowering for cardiovascular risk prevention. His view — supported by a substantial body of Mendelian randomization data — is that lower ApoB throughout life reduces atherosclerosis risk proportionally, and that starting lipid-lowering earlier provides more cumulative benefit than waiting until cardiovascular disease is diagnosed. He targets ApoB below 60-70 mg/dL for higher-risk individuals and uses statins, ezetimibe, or PCSK9 inhibitors to achieve this.

Low-dose aspirin: More controversial now than it was five years ago, as trials have shown that the bleeding risk of aspirin in primary prevention (preventing a first cardiovascular event) roughly offsets the cardiac benefit for most people. The risk-benefit calculation shifts toward benefit in higher cardiovascular risk individuals and those who have already had a cardiovascular event. This is a precision medicine decision based on individual risk profile rather than a blanket recommendation.

Metformin: The most widely used diabetes drug in the world is being studied as a longevity compound in the TAME trial. Its mechanisms — AMPK activation, mTOR inhibition, mitochondrial complex I modulation — overlap substantially with longevity biology. Some longevity physicians prescribe it off-label for healthy individuals with metabolic risk. The concern: metformin may blunt some exercise adaptations through its mitochondrial effects, which is significant given that exercise is the primary longevity intervention. This requires thoughtful weighing.

GLP-1 agonists: Semaglutide and tirzepatide have shown effects that extend well beyond their approved weight-loss and diabetes indications — substantial reductions in cardiovascular events, early signals suggesting possible effects on cancer risk and neurodegeneration. For individuals with significant obesity and metabolic dysfunction, these are powerful tools with a favorable benefit-risk profile. They’re increasingly part of the Medicine 3.0 pharmacological toolkit for appropriate patients.

The unifying thread: Medicine 3.0 pharmacology is precision and proactive rather than reactive and population-based. Drugs are used based on individual risk profiles, at the right time in the disease trajectory (early, before disease is established), and monitored against biomarker targets rather than symptoms.

Marcus eventually simplified his tracking. He kept the Oura ring for sleep and HRV — data that actually changed his behavior. He got a proper VO2 max test and discovered it was in the bottom third of his age group despite all his tracking. He restructured his training around Zone 2 and strength, got his ApoB tested (it was high enough to warrant a conversation with a physician about statins), and started treating sleep like the physiological priority it is rather than the inconvenience he’d always treated it as.

Six months later, he had better cardiovascular data than he’d had with three years of metric-obsessed gadgetry. The difference wasn’t more information. It was better frameworks for what to do with it.

That’s what Medicine 3.0 actually offers: not a protocol to follow, but a way of thinking that points toward the right actions for your specific biology, risks, and goals. The details matter less than getting the orientation right.

For the complete longevity framework, see the Anti-Aging Longevity Protocol — the hub article that connects all these pieces into an integrated system.

Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map